BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, Xie XJ, Brekken RA, Barnett CC, Bornmann WG, Gao J, Boothman DA. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Clin Cancer Res 2011;17:275-85. [PMID: 21224367 DOI: 10.1158/1078-0432.CCR-10-1983] [Cited by in Crossref: 83] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, Patel M, Parkinson EI, Wang Y, Williams NS, Gao J, Hergenrother PJ, Boothman DA. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Res 2012;72:3038-47. [PMID: 22532167 DOI: 10.1158/0008-5472.CAN-11-3135] [Cited by in Crossref: 90] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
2 Glorieux C, Buc Calderon P. Cancer Cell Sensitivity to Redox-Cycling Quinones is Influenced by NAD(P)H: Quinone Oxidoreductase 1 Polymorphism. Antioxidants (Basel) 2019;8:E369. [PMID: 31480790 DOI: 10.3390/antiox8090369] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
3 Silvers MA, Deja S, Singh N, Egnatchik RA, Sudderth J, Luo X, Beg MS, Burgess SC, DeBerardinis RJ, Boothman DA, Merritt ME. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. J Biol Chem 2017;292:18203-16. [PMID: 28916726 DOI: 10.1074/jbc.M117.813923] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 8.2] [Reference Citation Analysis]
4 Wu L, Zhang C. Synthesis and antitumor activity evaluation of novel substituted 5H-benzo[i][1,3,4]thiadiazolo[3,2-a]quinazoline-6,7-diones. RSC Adv 2016;6:28555-62. [DOI: 10.1039/c6ra03323g] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
5 Lewis JE, Costantini F, Mims J, Chen X, Furdui CM, Boothman DA, Kemp ML. Genome-Scale Modeling of NADPH-Driven β-Lapachone Sensitization in Head and Neck Squamous Cell Carcinoma. Antioxid Redox Signal 2018;29:937-52. [PMID: 28762750 DOI: 10.1089/ars.2017.7048] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
6 Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson VE, Pink JJ, Li LS, Patel M, Cao L, Moore Z, Rommel A, Boatman M, Lewis C, Euhus DM, Bornmann WG, Buchsbaum DJ, Spitz DR, Gao J, Boothman DA. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Mol Cancer Ther 2013;12:2110-20. [PMID: 23883585 DOI: 10.1158/1535-7163.MCT-12-0962] [Cited by in Crossref: 64] [Cited by in F6Publishing: 42] [Article Influence: 7.1] [Reference Citation Analysis]
7 Cao L, Li LS, Spruell C, Xiao L, Chakrabarti G, Bey EA, Reinicke KE, Srougi MC, Moore Z, Dong Y, Vo P, Kabbani W, Yang CR, Wang X, Fattah F, Morales JC, Motea EA, Bornmann WG, Yordy JS, Boothman DA. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Antioxid Redox Signal 2014;21:237-50. [PMID: 24512128 DOI: 10.1089/ars.2013.5462] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
8 Ayars M, O'Sullivan E, Macgregor-Das A, Shindo K, Kim H, Borges M, Yu J, Hruban RH, Goggins M. IL2RG, identified as overexpressed by RNA-seq profiling of pancreatic intraepithelial neoplasia, mediates pancreatic cancer growth. Oncotarget 2017;8:83370-83. [PMID: 29137350 DOI: 10.18632/oncotarget.19848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
9 Zhao W, Jiang L, Fang T, Fang F, Liu Y, Zhao Y, You Y, Zhou H, Su X, Wang J, Liu S, Chen Y, Wan J, Huang X. β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation. Front Oncol 2021;11:747282. [PMID: 34676172 DOI: 10.3389/fonc.2021.747282] [Reference Citation Analysis]
10 Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 2012;83:1033-40. [PMID: 22209713 DOI: 10.1016/j.bcp.2011.12.017] [Cited by in Crossref: 181] [Cited by in F6Publishing: 170] [Article Influence: 16.5] [Reference Citation Analysis]
11 Moore Z, Chakrabarti G, Luo X, Ali A, Hu Z, Fattah FJ, Vemireddy R, DeBerardinis RJ, Brekken RA, Boothman DA. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone. Cell Death Dis 2015;6:e1599. [PMID: 25590809 DOI: 10.1038/cddis.2014.564] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 8.6] [Reference Citation Analysis]
12 Motea EA, Huang X, Singh N, Kilgore JA, Williams NS, Xie XJ, Gerber DE, Beg MS, Bey EA, Boothman DA. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers. Clin Cancer Res 2019;25:2601-9. [PMID: 30617135 DOI: 10.1158/1078-0432.CCR-18-2560] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
13 Zhou L, Chen J, Sun Y, Chai K, Zhu Z, Wang C, Chen M, Han W, Hu X, Li R, Yao T, Li H, Dong C, Shi S. A self-amplified nanocatalytic system for achieving "1 + 1 + 1 > 3" chemodynamic therapy on triple negative breast cancer. J Nanobiotechnology 2021;19:261. [PMID: 34481495 DOI: 10.1186/s12951-021-00998-y] [Reference Citation Analysis]
14 Dhillon H, Chikara S, Reindl KM. Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage. Toxicol Rep 2014;1:309-18. [PMID: 25530945 DOI: 10.1016/j.toxrep.2014.05.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
15 Wu JM, Oraee A, Doonan BB, Pinto JT, Hsieh TC. Activation of NQO1 in NQO1*2 polymorphic human leukemic HL-60 cells by diet-derived sulforaphane. Exp Hematol Oncol 2015;5:27. [PMID: 27625902 DOI: 10.1186/s40164-016-0056-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
16 Oh GS, Kim HJ, Shen A, Lee SB, Yang SH, Shim H, Cho EY, Kwon KB, Kwak TH, So HS. New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity. Biomed Res Int 2016;2016:4048390. [PMID: 26881219 DOI: 10.1155/2016/4048390] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
17 Su X, Wang J, Jiang L, Chen Y, Lu T, Mendonca MS, Huang X. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage. Cancer Lett 2021;519:304-14. [PMID: 34329742 DOI: 10.1016/j.canlet.2021.07.040] [Reference Citation Analysis]
18 Kee JY, Han YH, Park J, Kim DS, Mun JG, Ahn KS, Kim HJ, Um JY, Hong SH. β-Lapachone Inhibits Lung Metastasis of Colorectal Cancer by Inducing Apoptosis of CT26 Cells. Integr Cancer Ther 2017;16:585-96. [PMID: 27923905 DOI: 10.1177/1534735416681638] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
19 Zaman S, Yu X, Bencivenga AF, Blanden AR, Liu Y, Withers T, Na B, Blayney AJ, Gilleran J, Boothman DA, Loh SN, Kimball SD, Carpizo DR. Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding. Mol Cancer Ther 2019;18:1355-65. [PMID: 31196889 DOI: 10.1158/1535-7163.MCT-18-1080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
20 Oh GS, Lee SB, Karna A, Kim HJ, Shen A, Pandit A, Lee S, Yang SH, So HS. Increased Cellular NAD+ Level through NQO1 Enzymatic Action Has Protective Effects on Bleomycin-Induced Lung Fibrosis in Mice. Tuberc Respir Dis (Seoul) 2016;79:257-66. [PMID: 27790277 DOI: 10.4046/trd.2016.79.4.257] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
21 Kowalczyk A, Kasprzak A, Poplawska M, Ruzycka M, Grudzinski IP, Nowicka AM. Controlled Drug Release and Cytotoxicity Studies of Beta-Lapachone and Doxorubicin Loaded into Cyclodextrins Attached to a Polyethyleneimine Matrix. Int J Mol Sci 2020;21:E5832. [PMID: 32823816 DOI: 10.3390/ijms21165832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Ferraz da Costa DC, Pereira Rangel L, Martins-Dinis MMDDC, Ferretti GDDS, Ferreira VF, Silva JL. Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues. Molecules 2020;25:E893. [PMID: 32085381 DOI: 10.3390/molecules25040893] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
23 Beg MS, Huang X, Silvers MA, Gerber DE, Bolluyt J, Sarode V, Fattah F, Deberardinis RJ, Merritt ME, Xie XJ, Leff R, Laheru D, Boothman DA. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. J Surg Oncol 2017;116:83-8. [PMID: 28346693 DOI: 10.1002/jso.24624] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
24 Chakrabarti G, Moore ZR, Luo X, Ilcheva M, Ali A, Padanad M, Zhou Y, Xie Y, Burma S, Scaglioni PP, Cantley LC, DeBerardinis RJ, Kimmelman AC, Lyssiotis CA, Boothman DA. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Cancer Metab 2015;3:12. [PMID: 26462257 DOI: 10.1186/s40170-015-0137-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 10.7] [Reference Citation Analysis]
25 Lee WS, Ham W, Kim J. Roles of NAD(P)H:quinone Oxidoreductase 1 in Diverse Diseases. Life (Basel) 2021;11:1301. [PMID: 34947831 DOI: 10.3390/life11121301] [Reference Citation Analysis]
26 Chakrabarti G, Gerber DE, Boothman DA. Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways. Clin Pharmacol 2015;7:57-68. [PMID: 25870517 DOI: 10.2147/CPAA.S79760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
27 Lundberg AP, Boudreau MW, Selting KA, Chatkewitz LE, Samuelson J, Francis JM, Parkinson EI, Barger AM, Hergenrother PJ, Fan TM. Utilizing feline oral squamous cell carcinoma patients to develop NQO1-targeted therapy. Neoplasia 2021;23:811-22. [PMID: 34246985 DOI: 10.1016/j.neo.2021.06.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Li LS, Reddy S, Lin ZH, Liu S, Park H, Chun SG, Bornmann WG, Thibodeaux J, Yan J, Chakrabarti G, Xie XJ, Sumer BD, Boothman DA, Yordy JS. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer. Mol Cancer Ther 2016;15:1757-67. [PMID: 27196777 DOI: 10.1158/1535-7163.MCT-15-0765] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
29 Chen X, Mims J, Huang X, Singh N, Motea E, Planchon SM, Beg M, Tsang AW, Porosnicu M, Kemp ML, Boothman DA, Furdui CM. Modulators of Redox Metabolism in Head and Neck Cancer. Antioxid Redox Signal 2018;29:1660-90. [PMID: 29113454 DOI: 10.1089/ars.2017.7423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
30 Froeling FEM, Swamynathan MM, Deschênes A, Chio IIC, Brosnan E, Yao MA, Alagesan P, Lucito M, Li J, Chang AY, Trotman LC, Belleau P, Park Y, Rogoff HA, Watson JD, Tuveson DA. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death. Clin Cancer Res 2019;25:7162-74. [PMID: 31527169 DOI: 10.1158/1078-0432.CCR-19-0302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
31 Lee HY, Parkinson EI, Granchi C, Paterni I, Panigrahy D, Seth P, Minutolo F, Hergenrother PJ. Reactive Oxygen Species Synergize To Potently and Selectively Induce Cancer Cell Death. ACS Chem Biol 2017;12:1416-24. [PMID: 28345875 DOI: 10.1021/acschembio.7b00015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
32 Shen Z, Prasai B, Nakamura Y, Kobayashi H, Jackson MS, McCarley RL. A Near-Infrared, Wavelength-Shiftable, Turn-on Fluorescent Probe for the Detection and Imaging of Cancer Tumor Cells. ACS Chem Biol 2017;12:1121-32. [PMID: 28240865 DOI: 10.1021/acschembio.6b01094] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
33 Liu F, Yu G, Wang G, Liu H, Wu X, Wang Q, Liu M, Liao K, Wu M, Cheng X, Hao H. An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer. PLoS One 2012;7:e42138. [PMID: 22848731 DOI: 10.1371/journal.pone.0042138] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
34 Madajewski B, Boatman MA, Chakrabarti G, Boothman DA, Bey EA. Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC. Mol Cancer Res 2016;14:14-25. [PMID: 26553038 DOI: 10.1158/1541-7786.MCR-15-0207-T] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
35 Zhang J, Xu Q, Ma D. Inhibition of thioredoxin reductase by natural anticancer candidate β-lapachone accounts for triggering redox activation-mediated HL-60 cell apoptosis. Free Radical Biology and Medicine 2022. [DOI: 10.1016/j.freeradbiomed.2022.01.019] [Reference Citation Analysis]
36 Pinho BR, Santos MM, Fonseca-Silva A, Valentão P, Andrade PB, Oliveira JM. How mitochondrial dysfunction affects zebrafish development and cardiovascular function: an in vivo model for testing mitochondria-targeted drugs. Br J Pharmacol 2013;169:1072-90. [PMID: 23758163 DOI: 10.1111/bph.12186] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 7.4] [Reference Citation Analysis]
37 Viera T, Patidar PL. DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition. Sci Rep 2020;10:20210. [PMID: 33214574 DOI: 10.1038/s41598-020-76850-4] [Reference Citation Analysis]
38 Lundberg AP, Francis JM, Pajak M, Parkinson EI, Wycislo KL, Rosol TJ, Brown ME, London CA, Dirikolu L, Hergenrother PJ, Fan TM. Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species. Invest New Drugs 2017;35:134-44. [PMID: 27975234 DOI: 10.1007/s10637-016-0414-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
39 Shukla K, Singh N, Lewis JE, Tsang AW, Boothman DA, Kemp ML, Furdui CM. MTHFD2 Blockade Enhances the Efficacy of β-Lapachone Chemotherapy With Ionizing Radiation in Head and Neck Squamous Cell Cancer. Front Oncol 2020;10:536377. [PMID: 33262939 DOI: 10.3389/fonc.2020.536377] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Ghanem MS, Monacelli F, Nencioni A. Advances in NAD-Lowering Agents for Cancer Treatment. Nutrients 2021;13:1665. [PMID: 34068917 DOI: 10.3390/nu13051665] [Reference Citation Analysis]
41 Chakrabarti G, Silvers MA, Ilcheva M, Liu Y, Moore ZR, Luo X, Gao J, Anderson G, Liu L, Sarode V, Gerber DE, Burma S, DeBerardinis RJ, Gerson SL, Boothman DA. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone. Sci Rep 2015;5:17066. [PMID: 26602448 DOI: 10.1038/srep17066] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
42 Kim HJ, Oh GS, Shen A, Lee SB, Choe SK, Kwon KB, Lee S, Seo KS, Kwak TH, Park R, So HS. Augmentation of NAD(+) by NQO1 attenuates cisplatin-mediated hearing impairment. Cell Death Dis 2014;5:e1292. [PMID: 24922076 DOI: 10.1038/cddis.2014.255] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
43 Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. Cancer Cell 2016;30:940-52. [PMID: 27960087 DOI: 10.1016/j.ccell.2016.11.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 13.6] [Reference Citation Analysis]